Non-health economists (henceforth referred to as ‘lay stakeholders’) are often asked to use the outputs of cost-effectiveness models to inform decisions, but they can find them difficult to understand. Conversely, health economists may have limited… Read More »How to explain cost-effectiveness models for diagnostic tests to a lay audience
Principles of Cost-Benefit Analysis, Cost-Utility Analysis, CEA, Cost-Consequences Analysis and Cost Analysis; techniques of CBA in health and health care; techniques of CUA and CEA in health and health care; techniques of CCA and CA in health and health care; decision theoretical approaches; pharmacoeco- nomics; economic evaluation of clinical devices; economic evaluation of public health interventions; outcome measures and their interpretation; evidence, efficacy and effectiveness; Health Technology Assessment; study design; risk and uncer- tainty; discounting; sensitivity analyses; modeling; systematic reviews and meta-analyses.
We’ve seen a few editorials and commentaries popping up about the EQ-5D-5L recently, in Health Economics, PharmacoEconomics, and PharmacoEconomics again. All of these articles have – to varying extents – acknowledged the need for NICE… Read More »Bad reasons not to use the EQ-5D-5L
The Irrelevance of Inference was a seminal paper published by Karl Claxton in 1999. In it he outlines a stochastic decision making approach to the evaluation of health technologies. A key point that he makes is… Read More »The irrelevance of inference: (almost) 20 years on is it still irrelevant?
The world’s highest impact factor medical journal, the New England Journal of Medicine (NEJM), seems to have been doing some soul searching. After publishing an editorial early in 2016 insinuating that researchers requesting data from trials… Read More »Data sharing and the cost of error